David Pelizzon Sells 18,000 Shares of OrthoPediatrics (NASDAQ:KIDS) Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) Director David Pelizzon sold 18,000 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $24.28, for a total value of $437,040.00. Following the completion of the sale, the director directly owned 6,863,464 shares in the company, valued at $166,644,905.92. This trade represents a 0.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

OrthoPediatrics Stock Performance

OrthoPediatrics stock opened at $23.32 on Friday. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28. The stock has a market cap of $608.89 million, a PE ratio of -13.88 and a beta of 0.98. OrthoPediatrics Corp. has a 12-month low of $14.42 and a 12-month high of $26.74. The business’s 50-day moving average price is $21.32 and its two-hundred day moving average price is $18.62.

OrthoPediatrics (NASDAQ:KIDS) last posted its earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. The firm had revenue of $70.51 million during the quarter, compared to analysts’ expectations of $68.21 million. As a group, analysts expect that OrthoPediatrics Corp. will post -1.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on KIDS shares. TD Cowen restated a “buy” rating on shares of OrthoPediatrics in a research report on Monday, June 15th. Weiss Ratings upgraded OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. Truist Financial set a $22.00 price objective on OrthoPediatrics in a report on Wednesday, August 5th. Piper Sandler restated an “overweight” rating and set a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Finally, BTIG Research upped their target price on OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $26.44.

Institutional Investors Weigh In On OrthoPediatrics

Several hedge funds have recently added to or reduced their stakes in the business. California State Teachers Retirement System grew its holdings in OrthoPediatrics by 397.1% during the 2nd quarter. California State Teachers Retirement System now owns 4,553 shares of the company’s stock worth $87,000 after acquiring an additional 3,637 shares during the last quarter. Nantahala Capital Management LLC acquired a new position in shares of OrthoPediatrics during the second quarter worth $4,636,002,000. Grandeur Peak Global Advisors LLC acquired a new position in shares of OrthoPediatrics during the second quarter worth $954,000. Bank of America Corp DE bought a new stake in shares of OrthoPediatrics in the second quarter worth $268,000. Finally, AWM Investment Company Inc. bought a new stake in shares of OrthoPediatrics in the second quarter worth $4,537,000. 69.05% of the stock is currently owned by institutional investors and hedge funds.

Key OrthoPediatrics News

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: OrthoPediatrics completed the full U.S. commercial launch of its 3P™ Pediatric Plating Platform® Hip System after more than 350 successful implantations during its limited release. The system expands the company’s pediatric trauma and deformity portfolio and could create a long-term revenue and market-share opportunity, though management did not provide specific financial guidance. 3P Pediatric Plating Platform Hip System launch
• Positive Sentiment: Analyst sentiment remains favorable. Piper Sandler raised its target to $25, Needham lifted its target to $35, and BTIG increased its target to $29, while maintaining positive ratings. MarketBeat data shows a “Moderate Buy” consensus with an average target of $26.44.
• Positive Sentiment: Recent quarterly results exceeded expectations: OrthoPediatrics reported a loss of $0.26 per share versus the estimated loss of $0.30, while revenue of $70.51 million surpassed the $68.21 million consensus estimate. BlackRock and other institutional investors also recently initiated or expanded positions.
• Neutral Sentiment: Reported short interest was listed at zero shares, but an invalid change figure makes the data unreliable and limits its usefulness for assessing short-selling pressure.
• Negative Sentiment: Director David R. Pelizzon and major shareholders associated with Squadron Capital and Jennifer N. Pritzker sold a combined 38,300 shares for approximately $943,302 across August 24–26, at prices ranging from $24.28 to $25.75. The sales reduced their position by roughly 0.56%, leaving ownership of about 6.86 million shares. While modest relative to their remaining stake, repeated insider selling may weigh on investor sentiment, particularly with the stock near its 52-week high. SEC insider transaction filing

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.